Sorafenib
Treatment for Liver Cancer Due To Nash
Typical Dosage: 400mg orally twice daily
Effectiveness
70%
Safety Score
45%
Clinical Trials
10
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
400mg orally twice daily
Time to Effect
1-2 months
Treatment Duration
until disease progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$7,000
Side Effect Mgmt:$8,000
Total Annual:$65,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$2,166,667
Cost per Remission
$13,000,000
Comparison vs Placebo
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Sorafenib Outcomes
for Liver Cancer Due To Nash
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+3%
Remission Rate
+0.5%
Common Side Effects
Diarrhea
+55%
Palmar-plantar erythrodysesthesia
+50%
Fatigue
+40%
Rash
+40%
Weight loss
+30%
Hypertension
+20%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov